Evaluation of Dapagliflozin Taken Twice-daily
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.
Also called NCT01217892
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 400 participants
- Sponsor
- Registry
-
NCT01217892
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Germany, Hungary, Romania, Slovakia, South Africa, Switzerland, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01217892. Randomized; quadruple masking; primary purpose treatment. Start 2010-11 (registry gives no type); primary completion 2011-08 (actual). Results posted on 2013-11-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Dapagliflozin Taken Twice-daily
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- dapagliflozin
- Intervention (Drug)
- dapagliflozin
- Intervention (Drug)
- dapagliflozin
- Intervention (Drug)
- metformin
- Intervention (Drug)
- placebo
- Lead sponsor
- AstraZeneca
- Collaborator
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct01217892- Content hash
cb80846f63aa2443497d65b11589ecd9979fd331e580f53ca424fe3b5fc1f4f8